MK-0646, Etoposide, and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Peter Ellis, MD
Margaret and Charles Juravinski Cancer Centre
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, Canada
- Ottawa Health Research Institute - General Division
Ottawa, Ontario, Canada
- Univ. Health Network-Princess Margaret Hospital
Toronto, Ontario, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 16 Dec 2009
- Primary completion
- 15 Mar 2012
- Completion
- 4 Jul 2012
- Last update posted
- 4 Aug 2023
- Registered enrollment
- 12
- Registry id
- NCT00869752
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.